110 completed, 21 terminated, 17 recruiting, 9 active not recruiting. 65 Phase 2, 49 Phase 3, 46 Phase 1, 9 Phase 4, 3 Early Phase 1.
Follow PPD Development, LP: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002 Intervention D SLS-002, Intervention D Placebo - Post Traumatic Stress Disorder | Phase 2 | Suspended | Global Coalition for Adaptive Research | 200 | 2028-05-01 | 2026-05-20 |
| Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo - Post Traumatic Stress Disorder | Phase 2 | Not yet recruiting | Global Coalition for Adaptive Research | 200 | 2027-08-01 | 2026-05-20 |
| Efficacy of Tezepelumab in Peanut Oral Immunotherapy Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab - Peanut Allergy | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 62 | 2026-07-27 | 2026-10-22 |
| A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo - Lyme Disease | Phase 2 | Active not recruiting | Tarsus Pharmaceuticals, Inc. | 722 | 2026-03-09 | 2026-07-09 |
| Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) JTE-162 - Cryopyrin-associated Periodic Syndromes (CAPS) | Phase 1 | Completed | Akros Pharma Inc. | 5 | 2026-02-02 | 2026-10-09 |
| Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) Obecabtagene autoleucel - Lupus Nephritis | Phase 2 | Recruiting | Autolus Limited | 35 | 2026-01-16 | 2026-08-24 |
| Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users Anifrolumab - Systemic Lupus Erythematosus | Phase 4 | Recruiting | AstraZeneca | 16 | 2026-01-16 | 2026-09-16 |
| The Anifrolumab PRIM Program Anifrolumab - Systemic Lupus Erythematosus | Recruiting | AstraZeneca | 240 | 2025-11-07 | 2026-09-11 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab Cohort C: bevacizumab, Cohort C: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-10-28 | 2026-07-31 |
| A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence VMB-100 - Stress Urinary Incontinence | Phase 2 | Withdrawn | Versameb AG | 2025-09-01 | 2025-12-05 | |
| Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users Anifrolumab - Systemic Lupus Erythematosus | Recruiting | AstraZeneca | 442 | 2025-07-01 | 2026-09-02 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab Cohort A: vilobelimab, Cohort A: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-06-21 | 2026-07-31 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 600 | 2025-06-10 | 2026-07-31 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart Cohort B: paridiprubart, Cohort B: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-06-10 | 2026-07-31 |
| Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging Contrast-Enhanced Ultrasound - Focal Liver Lesions | Phase 4 | Recruiting | GE Healthcare | 50 | 2025-01-20 | 2026-03-04 |
| To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension MANP, Placebo Matched control - Difficult to Control Hypertension | Phase 2 | Recruiting | E-Star BioTech, LLC | 120 | 2024-11-17 | 2026-09-23 |
| Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers Bepirovirsen, Placebo - Hepatitis B | Phase 1 | Completed | GlaxoSmithKline | 46 | 2024-07-18 | 2026-07-10 |
| A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers GEH200520 Injection and GEH200521 (18F) Injection, Static - PET/CT scan - Healthy Volunteers | Phase 1 | Completed | GE Healthcare | 22 | 2024-07-02 | 2026-03-06 |
| Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) CAB LA - HIV Infections | Phase 3 | Active not recruiting | ViiV Healthcare | 2996 | 2024-05-14 | 2026-07-30 |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera Givinostat, Hydroxyurea - Polycythemia Vera | Phase 3 | Recruiting | Italfarmaco | 220 | 2024-03-26 | 2026-03-25 |
Showing 20 of 172. Sign in to see all of them.
Arthritis, Rheumatoid (8) · HIV Infections (7) · Lupus Erythematosus, Systemic (7) · Acquired Immunodeficiency Syndrome (5) · Asthma (5) · Infections (5) · Stress Disorders, Post-Traumatic (5) · Acute Lung Injury (4) · Carcinoma, Non-Small-Cell Lung (4) · Crohn Disease (4) · Hepatitis C, Chronic (4) · Respiratory Distress Syndrome (4) · Acute Pain (3) · Arthritis, Psoriatic (3) · Autoimmune Diseases (3)
fospropofol (6) · Injections (5) · Diclofenac (4) · ocrelizumab (4) · Abatacept (3) · Certolizumab Pegol (3) · DWP450 (3) · Mycophenolic Acid (3) · Prednisone (3) · Ribavirin (3) · Tacrolimus (3) · anifrolumab (3) · pembrolizumab (3) · prabotulinumtoxin A (3) · ATL 146e (2)
United States (133) · Germany (27) · Canada (25) · Spain (22) · France (21) · United Kingdom (21) · Poland (19) · Italy (18) · Belgium (17) · Brazil (15) · Hungary (15) · Australia (13) · Argentina (12) · Mexico (11) · Israel (10)
James Jones, MD,PharmD (3) · Rui Avelar, MD (3) · Dan Levitt, MD (2) · David B Bharucha, MD, PhD, FACC (2) · Dennis Hruby, PhD (2) · Eduardo Tschen, MD (2) · James Jones, MD, PharmD (2) · Richard B Lipton, MD (2) · Stewart J Tepper, MD (2)
PMID 26494831, PMID 36005278, PMID 19805455, PMID 22052917, PMID 24107072, PMID 25082288, PMID 25701171, PMID 26045340, PMID 26729653, PMID 26980471, PMID 27207107, PMID 27629486, PMID 27678541, PMID 28401876, PMID 28552382, PMID 28575536, PMID 28814432, PMID 29030361, PMID 29158123, PMID 29561248, PMID 30181096, PMID 30357272, PMID 30476723, PMID 31520897, PMID 31725015, PMID 32028209, PMID 32066536, PMID 32219359, PMID 32265500, PMID 33311560, PMID 34158057, PMID 34352924, PMID 34358493, PMID 34747368, PMID 34913844, PMID 35129374, PMID 35472243, PMID 36906345, PMID 36966905, PMID 37029298, PMID 37246588, PMID 37459248, PMID 37678222, PMID 38019656, PMID 38408457, PMID 38491795, PMID 38515183, PMID 38804779, PMID 39015350, PMID 39225890
UM1AI109565 (7), 2014 (6), 2023 (3), 2008 (2), 2009 (2), 2015 (2), 2018 (1), 2019 (1), U01AI125050 (1), U01AI136816 (1), U01AI138909 (1), U01NS032228 (1)